In the present PERSIST study, our objective was to assess the efficacy and safety of administering extended adjuvant pyrotinib treatment following trastuzumab-based adjuvant therapy in patients with high-risk, HER2-positive early or locally advanced breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.